Diabetes and beta-adrenergic blockage are risk factors for metastatic prostate cancer

We evaluated the influence of comorbidity inferred risks for lymph node metastasis (pN1) and positive surgical margins (R1) after radical prostatectomy in order to optimize pretherapeutic risk classification. We analyzed 454 patients after radical prostatectomy (RP) between 2009 and 2014. Comorbidit...

Full description

Saved in:
Bibliographic Details
Published in:World journal of surgical oncology 2017-02, Vol.15 (1), p.50-50, Article 50
Main Authors: Krönig, Malte, Haverkamp, Christian, Schulte, Antonia, Heinicke, Laura, Schaal, Kathrin, Drendel, Vanessa, Werner, Martin, Wetterauer, Ulrich, Schultze-Seemann, Wolfgang, Jilg, Cordula Annette
Format: Article
Language:English
Subjects:
Adrenergic beta-agonists
Adrenergic beta-Antagonists - adverse effects
Aged
Combined Modality Therapy
Complications and side effects
Development and progression
Diabetes Mellitus - physiopathology
Diabetics
Follow-Up Studies
Humans
Lymphatic Metastasis
Male
Middle Aged
Neoplasm Grading
Neoplasm Staging
Prognosis
Prostate cancer
Prostatectomy - adverse effects
Prostatic Neoplasms - etiology
Prostatic Neoplasms - secondary
Prostatic Neoplasms - surgery
Risk factors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We evaluated the influence of comorbidity inferred risks for lymph node metastasis (pN1) and positive surgical margins (R1) after radical prostatectomy in order to optimize pretherapeutic risk classification. We analyzed 454 patients after radical prostatectomy (RP) between 2009 and 2014. Comorbidities were defined by patients' medication from our electronic patient chart and stratified according to the ATC WHO code. Endpoints were lymph node metastasis (pN1) and positive surgical margins (R1). Rates for pN1 and R1 were 21.4% (97/454) and 29.3% (133/454), respectively. In addition to CAPRA and Gleason score, we identified diabetes as a significant medication inferred risk factor for pN1 (OR 2.9, p = 0.004/OR 3.2, p = 0.001/OR 3.5, p = 0.001) and beta-blockers for R1 (OR 1.9, p = 0.020/OR 2.9, p = 0.004). Patients with diabetes showed no statistically significant difference in Gleason score, CAPRA Score, PSA, and age compared to non-diabetic patients. We identified diabetes and beta1 adrenergic blockage as significant risk factors for lymph node metastasis and positive surgical margins in prostate cancer (PCa). Patients at risk will need intensive pretherapeutic staging for optimal therapeutic stratification.
ISSN:1477-7819
1477-7819
DOI:10.1186/s12957-017-1117-4